Journal
INVESTIGATIONAL NEW DRUGS
Volume 38, Issue 6, Pages 1888-1898Publisher
SPRINGER
DOI: 10.1007/s10637-020-00955-w
Keywords
Carcinoembryonic Antigen-related Cell Adhesion Molecules (CEACAMs); Bispecific Antibody (BsAb); Bispecific T cell engager (BiTE); Chimeric Antigen Receptor T cell (CAR-T); Tumor immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81872412, 81602303, 31700736]
- Hubei Province Natural Science Foundation of China [2016CFB180]
- Foundation of Health and Family Planning Commission of Hubei Province [WJ2016-Y-02, WJ2016Y07]
- Hubei Province Scientific and Technological Research Project [Q20171306]
- Jingzhou Science and Technology Development Planning Project [JZKJ15063]
- Guangzhou Key Medical Discipline Construction Project
Ask authors/readers for more resources
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) contain 12 family members(CEACAM1,CEACAM3,CEACAM4,CEACAM5,CEACAM6,CEACAM7,CEACAM8,CEACAM16,CEACAM18,CEACAM19,CEACAM20 and CEACAM21)and are expressed diversely in different normal and tumor tissues. CEA (CEACAM5) has been used as a tumor biomarker since 1965. Here we review the latest research and development of the structures, expression, and function of CEACAMs in normal and tumor tissues, and their application in the tumor diagnosis, prognosis, and treatment. We focus on recent clinical studies of CEA targeted cancer immunotherapies, including bispecific antibody (BsAb) for radio-immuno-therapy and imaging, bispecific T cell engager (BiTE) and chimeric antigen receptor T cells (CAR-T). We summarize the promising clinical relevance and challenges of these approaches and give perspective view for future research. This review has important implications in understanding the diversified biology of CEACAMs in normal and tumor tissues, and their new role in tumor immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
